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The association between plasmid DNA distribution, the amount of Ag produced, Ag persistence and the
identity and localisation of cells presenting DNA-encoded Ag all have important consequences for both
quantitative and qualitative aspects of T cell responses induced by DNA vaccines. Using a variety of
approaches to detect and quantify the uptake of injected DNA, and the production and presentation of
DNA-encoded antigen, we report that injected DNA vaccines rapidly enter the peripheral blood from
the injection site and also reach muscle-draining lymph nodes directly as free DNA. 24h after plasmid
injection, MHCII+CD11b+B220−CD11clow/− cells in the draining and distal LNs and spleen contain pDNA.
Interestingly, we also observed pDNA+MHCIIlow/−CD11b+ within the bone marrow. Concomitantly, wentigen presentation
cells detected Ag-containing/expressing cells at both the injection site and in draining lymph nodes. Three
days after plasmid injection we detected rare pMHC+CD11c+ cells within secondary lymphoid tissue and
simultaneously observed Ag-speciﬁc CD4+ T cell accumulation and blastogenesis in these tissues. Our
results show that the events that determine the inductionofDNAvaccine immune responses occurwithin
d that
 days of DNA injection an
from resident BM cells.
. Introduction
Studies using protein have shown that the dose and duration
f Ag exposure can inﬂuence a number of important parame-
ers involved in T cell priming [1–4] including the acquisition of
ffector functions (e.g. Th1/Th2 phenotype) [5–7], memory cell dif-
erentiation and the size of the memory cell pool [8,9]. Thus, the
elationships between Ag dose and distribution, the number of
MHC complexes on an APC, costimulatory molecule interactions
nd pMHC/TcR stability determine the nature and extent of T cell
ctivation and function.Due to their non-replicative nature, DNA vaccines produce very
ow amounts of antigen in vivo (nanogram range), even when
sing the strongest viral promoters to drive Ag production [10].
owever, despite the low amounts of Ag involved, and although
Abbreviations: BLN, brachial lymph nodes; CLN, cervical lymph nodes; DLN,
raining lymph nodes; eGFP, enhanced green ﬂuorescent protein; ILN, inguinal
ymph nodes; PB, peripheral blood; pDNA, plasmid DNA; pMHC, peptide/MHC.
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primary immune responses can be difﬁcult to demonstrate [11],
recall responses are often potent [11]. This may be related to the
fact that, in contrast to other immunisation strategies where large
bolus doses of Ag are administered, DNA vaccines are characterised
by sustained production of small amounts of Ag [10]. Hence the
links between pDNA distribution following injection, amount of
Ag produced (and Ag persistence) and the identity and locali-
sation of cells presenting DNA-encoded Ag may have important
consequences for both quantitative and qualitative aspects of T
cell responses induced by DNA vaccines. However, the relation-
ship between cells that acquire pDNA, and those expressing or
presenting DNA-encoded Ag to naïve T cells is still unclear. Thus,
in the context of intramuscular DNA vaccination it will be impor-
tant to determine the distribution of cell-associated DNA; which
cells produce and present antigen; where, when and how long
they do this for; their phenotype and activation status and the
relationship between these parameters and CD4+ T cell activation.
To address some of these questions we have used a system based
on the E52–68 peptide of the MHC I-E molecule that allows us to
detect Ag, pMHCcomplexes andE-speciﬁc T cells directly in tissue
[1].
Open access under CC BY license.Our results show that the events that determine the induction
of DNA vaccine immune responses occurwithin hours/days of DNA
injectionand that the responsebecomes systemic very rapidly, pos-
siblywith involvement from resident BMcells. Such understanding
of the anatomical location, kinetics and cellular mechanisms
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nﬂuencing the development and maintenance of DNA vaccine-
nduced immune responses may be important for fully exploiting
heir potential by allowing rational design.
. Materials and methods
.1. Mice
CD4 T cells from TEa mice recognise the I-E-derived peptide
alpha 52–68 (E52–68) in the context of I-Ab [12]. TEa mice
xpressing the Thy1.1 allele were obtained from S. McSorley (Uni-
ersity of Minnesota, Minneapolis, MN) and used as Tg CD4 T cell
onors. C57 BL/6 (B6) (Thy1.2, Ly5.2) mice were purchased from
arlan UK Ltd. (Bicester, UK). Animals were maintained at the Cen-
ral Research Facility (University of Glasgow, Glasgow, UK) under
peciﬁc pathogen free conditions and all procedures performed
ccording to local andUKHomeOfﬁce regulations.Male and female
ice aged 6–12 weeks were used in all experiments.
.2. Antibodies and reagents
The mouse monoclonal Ab Y-Ae (murine IgG2b) has been
escribed previously [1,3,13]. Y-Ae recognises the E52–68 peptide
n the context of the I-Ab MHC Class II molecule [3,13]. Biotiny-
ated Y-Aewas prepared in-house using the Y-Ae hybridomakindly
rovided by S. McSorley (University of Minnesota). Biotinylated
sotype control mouse IgG2b was from Southern Biotechnol-
gy. Hamster anti-CD11c (N418) and hamster IgG isotype were
rom Serotec. Biotinylated goat anti-rabbit IgG and goat anti-
amster IgG were from Vector Laboratories Ltd. Rabbit anti-GFP
gG, Streptavidin-Alexa Fluor 647 (SA-AF647), Avidin-Cascade Blue
nd Alexa Fluor dye tyramide kits were from Molecular Probes
Invitrogen). Biotinyl tyramide signal ampliﬁcation kits were from
erkinElmer. The following ﬂuorochrome-conjugated and biotiny-
ated antibodies were from BD Pharmingen: anti-CD4/L3T4 (GK1.5
nd RM4-5), anti-CD69 (H1.2F3), anti-CD45R/B220 (RA3-6B2),
nti-CD11c (HL3), anti-CD11b (M1/70), anti-I-A/I-E (2G9), anti-V6
RR4.7), anti-V2 (B20.1), and anti-Ly5.2 (104). Streptavidin-APC
SA-APC) was from BD Pharmingen.
.3. Generation of E˛GFP fusion protein and protein puriﬁcation
The Escherichia coli strain expressing the ERFP fusion protein
as been described previously [1] and was kindly provided by M.K.
enkins and S. McSorley (University of Minnesota). This protein is
ncoded by an in-frame fusion between amino acids 45 and 73 of
he MHC Class II I-E molecule (containing E52–68) and the Red Flu-
rescent Protein, DsRed1 (Clontec). We constructed an alternative
ersion of this protein in pTrcHisTOPO (Invitrogen) by replacing the
FP coding sequence with the eGFP coding sequence from pEGFP-
1 (Clontech), to generate an EGFP gene fusion (pTrcHisEGFP).
xpression of EGFP protein was induced using 1mM IPTG for
6–18h and protein was puriﬁed using Ni-NTA Superﬂow resin
Qiagen). Puriﬁedproteinwas quantiﬁedusing Coomassie Plus Pro-
ein Assay Reagent (Pierce).
.4. DNA vaccine constructs
The plasmid pCI-ERFP was prepared by PCR cloning of the
RFP coding sequence from the previously described plasmid
TrcHisERFP [1] into the mammalian expression plasmid pCI-
eo (Promega). The plasmid pCI-EGFP was created by PCR using
TrcHisEGFP as template. The plasmid pCI-OVAeGFP expresses a
ytosolic OVAeGFP fusion protein. (2010) 1620–1634 1621
2.5. Cell lines, transfection and cross-presentation assay
HeLa cells were cultured in DMEM supplemented as described
above and were transfected using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. To ensure that
pCI-EGFP- and pCI-ERFP-expressed EGFP and ERFP proteins
could be correctly processed and the E peptide surface displayed,
we set up co-culture, cross-presentation assays using transfected
HeLa cells as a source of E antigen and B6 (I-E−/I-Ab+) BMDCs as
APCs. HeLa cells (obtained from ECACC) were seeded in chamber
slides and transfected with pCI-EGFP, pCI-ERFP, or control plas-
mids pCIneo or pCI-OVAeGFP. 24h post-transfection, B6 BMDCs
prepared as described previously [14], were added and cells were
co-cultured to allow DCs to acquire plasmid-expressed Ag. BMDC
cultures typically contained 85–90% CD11c+ cells. 4 h later, LPS
(from Salmonella equi-abortus, Sigma) was added to a ﬁnal concen-
tration of 1g/ml to induce DC maturation. After 24h co-cultured
CD11c+ DCs were analysed for GFP and surface Y-Ae staining
by ﬂow cytometry and by immunoﬂuorescence staining of cells
seeded in chamber slides.
2.6. Adoptive transfer
Lymph node and spleen cell suspensions from TEa Tg mice
were prepared as previously described [1]. The E peptide-speciﬁc
Tg CD4 T cells were identiﬁed as CD4+V6+V2+. B6 recipients
received 0.5–1×106 Tg T cells in 0.2ml intravenously in the lateral
tail vein1dayprior to immunisation. In someexperimentsTgTcells
were labelled with CFSE prior to adoptive transfer as previously
described [15].
2.7. Immunisation
ForEGFPprotein immunisation, differentdoses (100g, 10g,
1g, 100ng, 10ng and 1ng) diluted in PBS, were administered
subcutaneously in the neck scruff, each with 1g/dose LPS (S. equi-
abortus, Sigma) as adjuvant. Control mice received PBS containing
1g LPS. LPS was added in order to activate APC and drive them
from an antigen acquisitive to antigen presenting state as widely
described in the literature. For intramuscular DNA immunisation
mice received 50g plasmid DNA diluted in endotoxin-free PBS in
a 50l ﬁnal volume in both tibialis anterior (TA) muscles.
2.8. Preparation of cells for ﬂow cytometry
At various times after EGFP subcutaneous protein immuni-
sation and subcutaneous DNA injection, cervical (CLN), brachial
(BLN) and inguinal (ILN) lymph nodes were removed, macerated
through Nitex mesh (Cadish and Sons, London, UK) and digested
with 1mg/ml Collagenase A (Sigma) and 10g/ml DNase A (Roche
Diagnostics) in HBSS for 30min at 37 ◦C. EDTA was added to a ﬁnal
concentration of 10mMand cells incubated a further 5min at room
temperature to maximise the number of dendritic cells released
from tissues. Popliteal and inguinal lymph nodes that drain the
lower limbs, were removed at various times after intramuscular
DNA injection and single cell suspensions prepared as described
above. GFP+ cells were identiﬁed in the FL1 channel of the FAC-
sCalibur ﬂow cytometer (Becton Dickinson). Cells displaying E
peptide–MHC complexes were identiﬁed using biotinylated Y-Ae
and SA-APC. PE-conjugated anti-CD11c was used to identify den-
dritic cells. In adoptive transfer experiments, E-speciﬁc TEa T
cells were identiﬁed using Alexa Fluor 647-conjugated anti-CD90.1
(Thy1.1) (HIS51) (Serotec) and PE-conjugated anti-CD4. A FacsCal-
ibur ﬂow cytometer was used with CellQuest acquisition software
and FlowJo analysis software (Treestar).
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.9. Plasmid labelling and detection of labelled DNA in vivo
pCIneo or pCI-ERFP plasmid DNAwas labelled using the Label-
T Cy5 kit (Mirus Bio) according to the manufacturer’s instructions.
0g of labelled plasmid in 50l PBS was injected intramuscu-
arly (TA muscle) and at various times after injection, draining
opliteal and ILNs, distal CLNs and BLNs, spleens, peripheral blood
nd bone marrow were collected for ﬂow cytometry. Phenotypic
haracterisation of cells carrying pDNA-Cy5 was performed using
uorochrome-labelled lineage speciﬁc markers including MHC
lass II, CD45 (Ly5.2 allotype for B6 mice), CD11b, CD11c and B220.
.10. Detection of Ag and pMHC complexes in tissue sections
At various times after EGFP (or ERFP) protein or DNA immu-
isation, injection sites (skin or muscle) draining and non-draining
ymph nodes and spleens were excised and post-ﬁxed in 1%
araformaldehyde (PFA)/PBS for 2h. Tissues were quenched for
0min in 0.5% Gly-Gly (Sigma), followed by 2h in 10% sucrose/PBS,
hen overnight in 30% sucrose/PBS before embedding in OCT
edium (Miles, Elkart, USA) and snap freezing in liquid nitrogen.
e found that this ﬁxation procedure preserved GFP ﬂuores-
ence, which is often liable to diffusion in unﬁxed tissue, but
till preserved conformational epitopes including pMHC com-
lexes. 18–20m sections of TA muscles were mounted with
ectashield containing the nuclear stain DAPI (Vector) and exam-
ned for GFP ﬂuorescence. Frozen sections of lymph nodes, cut at
–8m were air-dried, rehydrated in PBS, permeabilised in 0.1%
riton X-100/PBS, washed brieﬂy in PBS, treated with 1%H2O2/0.1%
odium azide/PBS to destroy endogenous peroxidases, and blocked
sing the Avidin/Biotin blocking kit (Vector) and anti-CD 16/CD32
BD Pharmingen). The GFP signal in tissue sections was ampli-
ed using rabbit anti-GFP IgG, biotinylated goat anti-rabbit IgG,
A-HRP (Tyramide Signal Ampliﬁcation kit, PerkinElmer), biotinyl
yramide and SA-647 or SA-488. Y-Ae+ cells were localised using
iotinylated Y-Ae mAb, followed by SA-HRP, biotinyl tyramide and
ither SA-AF647 or Avidin-Cascade Blue. Control sections were
reated as above but were incubated with the Y-Ae isotype, i.e.
iotinylated mouse IgG2b. B cell follicles were stained using Paciﬁc
lue-conjugated anti-CD45R/B220 (prepared in-house) or FITC-
onjugated anti-CD45R/B220 for ERFP and pCI-ERFP samples.
D11c+ cells in Y-Ae-stained sections were demonstrated by ﬁrst
taining with Y-Ae as described above, followed by additional
2O2/azide treatment and avidin and biotin blocking, to remove
nreacted HRP and biotin/avidin, respectively. Sections were then
ncubated in either hamster anti-CD11c or hamster IgG (isotype
ontrol), biotinylated goat anti-hamster IgG, SA-HRP and Paciﬁc
lue tyramide. Slides were mounted in Vectashield and images
ere captured using an Olympus BX-50 microscope with colour
CD digital camera and OpenLab digital imaging software (Impro-
ision, Coventry, UK). In some images ﬂuorochromes were false
oloured to improve image colour contrast.
.11. Statistics
Results are expressed as mean± SE mean when n≥3 and
ean± range where n=2. Student’s unpaired t tests with two-
ailed distribution were used to calculate statistical signiﬁcance
p<0.05) when samples were normally distributed.
. Results.1. Establishing detection of Ag and pMHC complexes in vivo
ollowing protein immunisation
Elegant studies by Itano et al. [1] described a novel system for
tudyingAgdistribution, and identifying cells presentingAg in vivo,8 (2010) 1620–1634
in conjunction with Ag-speciﬁc CD4+ T cells recognising the same
pMHC complex. We adapted these tools to investigate Ag and APCs
in the context of DNA vaccination. The original study [1] utilised
an ERFP (or EDsRed) fusion protein for Ag detection. As oth-
ers have reported cytotoxicity and aggregation associated with
the DsRed1 protein used in this fusion protein and because we
wanted to be able to further amplify the Ag signal, we developed an
Ag detection system based on the monomeric eGFP. We modiﬁed
the system described previously by replacing the RFP(DsRed1)-
component with a sequence encoding eGFP and validated the
EGFP system for detection of both Ag and pMHC complexes
in vivo.
Subcutaneous immunisation with EGFP protein resulted in
marked heterogeneity in both Ag content and pMHC complex dis-
play in the cells of draining lymph nodes. Flow cytometric analysis
of lymph node suspensions from mice immunised 24h previ-
ously with 100g EGFP protein plus 1g LPS showed that about
2.3–2.7% of all live cellswere Y-Ae+ compared to about 0.4% for con-
trol mice immunised with LPS alone (Fig. 1A and B, upper panels).
The Y-Ae isotype control antibody mIgG2b was used to set positive
staining gates and showed approximately 0.2% background stain-
ing (Fig. 1A and B, lower panels). Hence, the maximum background
Y-Ae staining (LPS and isotype control) is approximately 0.4% and
stainingabove this level is consideredpositive staining.Background
staining could not be completely eliminated due to tissue autoﬂu-
orescence and the large numbers of cells that were acquired for
analysis.
ThemajorityofY-Ae+ cells found indraining lymphnodesat24h
post-injection were GFPlow/− or below the level of GFP detection
(∼2.0% of live cells, Fig. 1A, upper left quadrant) with only 0.7% of
live cells displaying a Y-Ae+GFPhigh phenotype (Fig. 1A, upper right
quadrant). Interestingly, there was considerable heterogeneity in
CD11c staining within the Y-Ae+ population (Fig. 1B) with several
differentpopulationswithdifferent levels ofY-Ae stainingorCD11c
expression clearly evident. In this experiment, approximately 50%
ofCD11chigh cells fromEGFP-immunisedmicewereY-Ae+ (Fig. 1B,
upper panel, upper right quadrant), however, there were a smaller
percentage (∼28%;∼0.6% of live cells)with a Y-Ae+CD11clow/− phe-
notype (Fig. 1B, upper panel, upper left quadrant). At present we
have not attempted to further characterise these Y-Ae+CD11clow/−
cells.
EGFP Ag was demonstrated at both the injection site (Fig. 1C)
and in the local draining lymph nodes (Fig. 1D and E) 30min after
injection. EGFP appeared to ﬂow fromone side of the lymphnode,
from the subcapsular sinus into the paracortical areas (Fig. 1E)
as has been observed previously for other protein Ags, including
ERFP [1]. To maximise the sensitivity of Ag detection in lymphoid
tissues, we used GFP-speciﬁc rabbit IgG to amplify the GFP signal
(Fig. 1F). At 24hwe observed that large areas of the draining lymph
nodes were Y-Ae+ (Fig. 1G) as has been reported previously [1]. B
cell follicular areas were not stained with Y-Ae, with the majority
of Y-Ae+ cells being found in the interfollicular areas, paracortex
and subcapsular sinus. As was observed by ﬂow cytometry, Y-Ae
staining co-localised with CD11c+ cells (Fig. 1H, yellow), however
there were some Y-Ae+CD11clow/− cells (red).
3.2. Dose-dependent detection of Ag and pMHC complexes
following protein immunisation
The maximum amount of Ag detected following DNA vaccina-
tion is known to be in the nanogram range in muscle and serum
[10,16], however the amount of Ag that reaches lymphoid tissues
is unknown. Estimates are that fewer than 2% of all CD11c+ cells
may contain plasmid-encoded Ag following transdermal gene gun
delivery [17] and it is not known how many of these cells present
Ag to naïve lymphocytes. Therefore we wished to establish sen-
C.M. Rush et al. / Vaccine 28 (2010) 1620–1634 1623
Fig. 1. Ag and pMHC complexes were detected in draining lymph nodes following EGFP immunisation. 24h after EGFP injection, ﬂow cytometry was used to assess the
proportion of live cells in pooled draining CLNs and BLNs that were GFP+, pMHC+ (i.e. Y-Ae+) and CD11c+ (A and B). Control mice received LPS only. Mouse IgG2b was used
as Y-Ae isotype control for each sample and was used to set positive and negative quadrant gates. Representative dot plots are shown for each group (n=3). Fluorescence
microscopy was used to demonstrate EGFP (green) in tissue sections of the injection site (C) and in draining CLNs (D and E), 30min after protein injection. The intrinsic GFP
signal was ampliﬁed using a GFP-speciﬁc polyclonal Ab (red in F). At 24h post-injection, large areas of the paracortex (pc) of DLNs were Y-Ae+ (G), whereas B cell follicle areas
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ostain with CD11c (red, indicated by arrows). (H) Fluorochromes were false colour
ata is shown. Scale bars show approximately 10m. (For interpretation of the re
rticle.)
itive methodologies to study those cells that acquire and present
NA-encodedAg, particularly in lymphoid tissue. To determine the
inimum amount of protein Ag that could be detected in vivo and
ow much Ag is needed to be able to detect cells displaying pMHC
omplexes, we administered a range of doses of EGFP protein and
xamined the draining lymphnodes for cell-associated Ag and cells
isplayingpMHCcomplexes. The aimof this protein injection study
as to demonstrate the sensitivity of the assay systems in a widely
tudied situation such as subcutaneous injection.at many Y-Ae cells were also CD11c (yellow), although some Y-Ae cells did not
improve colour contrast. Dotted lines indicate the periphery of LNs. Representative
es to colour in this ﬁgure legend, the reader is referred to the web version of the
Both Ag distribution and the proportion of GFP+ cellswere inﬂu-
enced by Ag dose (Fig. 2A and B). GFP+ cells were detected in
the CLNs (Fig. 2A and B), BLNs and ILNs (data not shown), 24h
after injection of 100g Ag (n=3, p<0.05). However, lower Ag
doses yielded far fewer GFP+ within both the CD11c+ (Fig. 2A) and
CD11clow/− (Fig. 2B) populations. Statistical signiﬁcance was only
demonstrated for 100g, 10g and 10ng doses, as often 1 out of 3
mice showed signiﬁcant variability from the other 2mice. Although
the percentage of GFP+ cells in the CD11clow/− population follow-
1624 C.M. Rush et al. / Vaccine 28 (2010) 1620–1634
Fig. 2. Dose-related detection of GFP-containing and pMHC+ cells in peripheral lymph nodes 24h after Ag injection. Different doses of EGFPAg (100g, 1g, 0.1g, 0.01g,
0.001g) each containing 1g LPS were administered by subcutaneous injection in the neck scruff. Mice immunised with PBS containing 1g LPS were used for controls
to establish the baseline staining and assay sensitivity. Draining proximal CLNs and BLNs were collected at 24h from individual mice. The proportion of GFP+ cells in gated
CD11chigh (A) and CD11clow/− (B) populations was determined for each sample by ﬂow cytometry and results expressed as group mean percentage± standard error of the
mean (SEM). The high proportion of apparently GFP+ CD11c+ cells in the PBS/LPS control (∼10–15%) is due to background autoﬂuorescence in the CD11c+ gate resulting from
the collection of the large numbers of cells needed for analysis of the small fraction (1–4%) of lymph node CD11c+ cells. If the mean autoﬂuorescence of the PBS control group
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vs subtracted (insets in A and B) from the mean percentage of the groups receiving
oses ranging from100g to 10ng. The proportion of CD11chigh and CD11clow/− cells
s the Y-Ae isotype control for each sample and used to set positive and negative g
npaired t-test, 2 way, assuming unequal variance) were made between the PBS con
ng 10g, 1g and 0.1g Ag doses appeared elevated compared to
BS/LPS control, particularly in draining CLN and BLN, these were
ot statistically signiﬁcant. The proportion of CD11clow/− cells con-
aining GFP following 100g Ag, was higher in the local cervical
nd brachial LNs than in more distal inguinal and axial LNs (data
ot shown). Backgroundcorrection, calculatedby subtractingmean
alues for PBS control from dose values revealed that GFP+ cells
ouldbedetectedat lowAgdoses (Fig. 2AandB, insets). Theamount
f cell-associatedGFP fromdoses less than100gmaybebelowthe
evel of sensitivity of GFP detection by ﬂow cytometry. Lymphoid
issue autoﬂuorescence also impacts on assay sensitivity.
Analysis of cells displaying pMHC complexes (i.e. Y-Ae+)
evealed that we could detect complexes in more than 20% of all
D11chigh cells in the draining CLNs (Fig. 2C) and BLNs (not shown)
t the 100g dose. Decreasing amounts of Ag resulted in corre-
ponding decreases in the percentages of CD11c+Y-Ae+ cells, with
he limit of detection of pMHC complexes between 1g and 100ng
f administered Ag. pMHC complex detection in CD 11clow/− cells
howed a similar trend. As was the case for detection of GFP+ cells,
ariability within the small group (n=3), limited statistical signiﬁ-–100g EGFP, it is clear that GFP cells are found in draining LNs for all antigen
aying pMHC complexes is shown in (C) and (D), respectively.Mouse IgG2bwas used
rror bars show SEM for each group, where n=3. Statistical comparisons (Students’
roup and each dose and asterisk (*) indicates statistical signiﬁcance where p<0.05.
cance. Both the CD11chigh and CD11clow/− populations also showed
increased, although not statistically signiﬁcant, Y-Ae mean ﬂuores-
cence down to a dose of 100–10ng Ag (data not shown).
These results indicate that with controlled and careful detailed
analyses, we can detect both Ag and cells displaying pMHC com-
plexes followingadministrationof about1g–100ngAg, and this is
theupper limit of Ag thatwemight expect to beproduced following
pDNA injection.
3.3. Kinetics of Ag distribution and pMHC complex formation
following protein immunisation
The kinetics of Ag distribution and presentation is likely to vary
depending on the route (e.g. subcutaneous vs. intramuscular) and
the type of immunisation (e.g. protein vs. pDNA), and we wished to
determine the kinetics of appearance of pMHC complexes for both
protein and pDNA immunisation. The aim of this protein injection
study was to study the kinetics of Ag distribution in a widely stud-
ied situation such as subcutaneous injection. As has been shown
for ERFP previously [1], EGFP+ cells, i.e. cell-associated EGFP,
C.M. Rush et al. / Vaccine 28 (2010) 1620–1634 1625
Fig. 3. Kinetics of appearance of EGFP and pMHC positive cells in lymph nodes draining the injection site. Flow cytometry was used to assess the proportion of CD11chigh
and CD11clow/− cells carrying EGFP (A and B) and displaying pMHC complexes (C–F) at 1h, 4h, 12h, 24h and 48h after EGFP/LPS injection. Cell suspensions were prepared
from the CLNs and BLNs of mice receiving either 100g EGFP/LPS or PBS/LPS alone. Live cells were gated for CD11c expression and CD11chigh and CD11clow/− gated cells
were analysed separately for both GFP and Y-Ae staining. The mean percentage of CD11c+ cells in CLNs (closed circles, ) and BLNs (closed triangles, ), that are GFP+ at
each timepoint, are shown in (A). Open circles (©) and open triangles () represent background staining in CLNs and BLNs of control mice receiving PBS/LPS only. Results for
CD11clow/− cells are shown in (B). Themean percentage of CD11c+ cells in CLNs, at each timepoint, that are surface Y-Ae+ following EGFP () or PBS/LPS control immunisation
( itive
s N are
E terisk
s
c
A
c
c
c©) are shown in (C). Mouse IgG2b was used as the Y-Ae isotype control to set pos
taining in CD11clow/− cells. Kinetic results for CD11chigh and CD11clow/− cells in BL
GFP/LPS group (n=3) and control PBS/LPS group (n=3) for each timepoint and as
tandard error of the means (SEM).an be found in the neck-draining CLNs and BLNs within 1h of
g injection in both CD11chigh (Fig. 3A) and CD11clow/− (Fig. 3B)
ells. Fluorescence microscopy indicated that in addition to this
ell-associated Ag, much of the injected Ag appeared to be extra-
ellular (Fig. 1D). After this initial wave of antigen positive cells inand negative gates and is represented as open symbols in (C). (D) Results for Y-Ae
shown in (E) and (F), respectively. Statistical comparisons were made between the
(*) indicates signiﬁcance where p<0.05 using the Student’s t-test. Error bars showthe draining LNs, the number of cells carrying or associated with
Ag decreased until 12–24h when GFP+ cells reappeared in draining
LNs. CD11c+GFP+ cells reappeared in the BLNs prior to their reap-
pearance in the CLNs (Fig. 3A). Itano et al. [1] suggested that these
Ag-bearing cells have migrated from the injection site. Although
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Fig. 4. DNAvaccine expression constructs used in this study. (A) Constructswere all based on the pCIneo (Promega). pCI-CytOVAeGFP encodes a cytosolic formof anOVAeGFP
fusion protein for simultaneous detection of OVA and eGFP in vivo. pCI-EGFP encodes the EGFP fusion protein described above and is used for identifying cells expressing
(GFP) and presenting (E) the Ag EGFP. pCI-ERFP is similar to pEGFP except for the substitution of RFP. (B–E) In vitro Ag presentation assay to demonstrate that plasmid-
expressed EGFP and ERFP is processed and the E peptide displayed on the surface of APCs in vitro. HeLa cells were transfected with the plasmid constructs pCIneo,
pCI-OVAeGFP, pCI-EGFP, or pCI-ERFP and B6 bone marrow DCs (+LPS) were added and cells were co-cultured for 24h to allow DCs to acquire, process and display plasmid-
expressed Ag. For positive controls, HeLa/DC co-cultures were pulsed with EGFP or ERFP protein. Cells were harvested, stained for CD11c and pMHC complexes using Y-Ae
or isotype control (mIgG2b) and analysed byﬂowcytometry. (B) DCs pulsedwith EGFPwere Y-Ae+ (surface Epeptide:MHCClassII complex) (black),whereas both unpulsed
DCs (blue) and isotype controls (grey shading) show minimal staining. (C) Y-Ae+ DCs were only present when DCs were co-cultured with pCI-EGFP-transfectants (black) but
not with pCIneo (blue) nor pCI-CytOVAeGFP (red) control transfectants. Isotype controls showed little staining (grey shading). Flow cytometry results for pCI-ERFP were
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timilar to those for pCI-EGFP and are not shown. (D) Immunoﬂuorescence staini
ells (red) with a larger dendritic-like cell also staining with Y-Ae mAb (green). Inta
lso present in pCI-ERFP-transfected HeLa/DC cultures (green). A transfected HeLa
olour in this ﬁgure legend, the reader is referred to the web version of the article.)
any of these LN immigrants are likely to be dendritic cells, some
D11clow/− cells also appeared in the LN at this timepoint (Fig. 3B).
e have not attempted to further characterise these cells. Fol-
owing the initial peak in immigration into the LNs, numbers of
FP+CD11c+ and GFP+CD11clow/− cells gradually declined over the
ext 24h and we were still able to detect GFP+ cells at 48h (Fig. 3A
nd B) and low numbers 3–7 days after immunisation (data not
hown). In all cases resultswere compared to controlmice that had
eceived LPS only and showed only minimal background staining.
The appearance of Y-Ae+ cells in both the CLNs and BLNs,
howed similar kinetics to that of GFP+ cells, with small num-
ers of CD11chigh and CD11clow/− displaying pMHC complexes as
arly as 1h after Ag injection (Fig. 3C–F). The CLNs (Fig. 3C and D)
nd BLNs (Fig. 3E and F) showed similar numbers of Y-Ae+ cells
t the timepoints examined, although statistical analysis revealed
hat the %Y-Ae+ cells in CLNs were statistically higher than con-
rols at a number of timepoints whereas %Y-Ae+ cells in BLNs were
igniﬁcantly above controls at only the 12h timepoint. By 4h post-
njection there were signiﬁcantly more Y-Ae+CD11c+ cells in the
LN compared to the LPS only control (Fig. 3A). Minimal staining
ith the isotype controlmIgG2b antibody conﬁrmed the speciﬁcity
f the Y-Ae staining. The proportion of draining LN (CLN and BLN)
D11c+ and CD11clow/− cells displaying pMHC complexes peaked
etween 12 and 24h after immunisation and then decreased by
8h. In other experiments we were still able to detect pMHC+ cells
ore than 5 days after immunisation (data not shown). Both GFP+
nd Y-Ae+ cells were detected in more distal lymph nodes, includ-
ng the inguinal and axial LNs, although the proportion and mean
uorescence was lower than in the LNs directly draining the injec-
ion site (data not shown).cytospins of ERFP protein-pulsed HeLa/DCs shows, ERFP-containing monocytic
RFP Ag is also visible within the Y-Ae+ cell (indicated by arrow). (E) Y-Ae+ cells are
red) can be seen adjacent to the Y-Ae+ cell. (For interpretation of the references to
3.4. Expression of Ag and pMHC from DNA vaccine constructs in
vitro
Before using pCI-EGFP and pCI-ERFP DNA vaccine constructs
(Fig. 4A) for detection of Ag and pMHC complexes in vivo, we
wanted to conﬁrm that pCI-EGFP- and pCI-ERFP-expressed
EGFP and ERFP proteins could be correctly processed and the E
peptide surface displayed on APCs. However because the transfec-
tion efﬁciency of primary DCs, particularly by non-viral vectors is
relatively low [18], we established a co-culture assay using trans-
fected HeLa cells as an Ag source and B6 (I-E−/I-Ab+) BMDCs as
APCs. In this cross-presentation assay, Ag is transferred to the
DCs and processed for peptide presentation in complex with I-Ab.
Hence, positive Y-Ae staining on DCs would indicate the pres-
ence of plasmid-derived E peptide. HeLa cells were transfected
with the plasmid constructs pCI-EGFP, or pCI-ERFP or the con-
trol constructs pCIneo or pCI-OVAeGFP. 24h post-transfection, B6
BMDCs were added and cells were co-cultured for 24h to allow
DCs to acquire, process and display plasmid-expressed Ag. For pos-
itive controls, HeLa/DC co-cultures were pulsed with EGFP or
ERFP protein for 16h. Cells were harvested, stained for CD11c
and Y-Ae or CD11c and the Y-Ae isotype control (mouse IgG2b)
and analysed by ﬂow cytometry. DCs pulsed with EGFP were
Y-Ae+ (surface E peptide:MHC ClassII complex) (Fig. 4B, black his-
togram), whereas both unpulsed DCs (blue histogram) and isotype
controls (grey shading) show minimal staining. Flow cytomet-
ric analysis of CD11c+ cells from plasmid-transfected HeLa/DC
cultures, revealed Y-Ae+ DCs when DCs were co-cultured with
pCI-EGFP-transfectants (Fig. 4C, black histogram) but not with
pCIneo (blue histogram) or pCI-OVAeGFP (red histogram) control
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Table 1
Phenotype of pDNA-Cy5+ cells in different tissues 24h after plasmid injection.
CD45 MHCII CD11b CD11c B220
LN + + + −>+ −>+
Spleen + + +>− −>+ −C.M. Rush et al. / Vac
ransfectants. Isotype controls showed little staining (grey shad-
ng). Flow cytometry results for pCI-ERFP were similar to those
or pCI-EGFP and are not shown. Immunoﬂuorescence staining of
RFP protein-pulsed HeLa/DCs grown in chamber slides, clearly
emonstrated the presence of both Ag-laden cells (red) and pMHC+
Y-Ae+) cells (green) (Fig. 4D). Some unprocessed ERFP can be
een in the cytosol of the Y-Ae+ cell (indicated by arrow). We also
emonstrated pMHC+ cells (green) in pCI-ERFP-transfected HeLa
onolayers co-cultured with BMDCs (Fig. 4E). In this example pCI-
RFP-transfected HeLa cells expressing the ERFP protein (red)
an be seen adjacent to a Y-Ae+ cell (green), suggesting that the
-Ae+ cell had acquired Ag or E peptide from another cell (i.e.
ross-presentation). These results indicate that our E-based DNA
accine constructs, in combination with the pMHC Ab Y-Ae, may
e useful tools for identifying cells presenting DNA-encoded Ag in
ivo.
.5. pDNA distribution following plasmid injection
We prepared ﬂuorescently labelled plasmid according to stan-
ard protocols, injected labelled plasmid and attempted to identify
ts distribution and the phenotype of associated cells. Tissues
ncluding the TA muscle, draining popliteal and inguinal LNs,
istal cervical and brachial LNs, spleen, peripheral blood and
one marrow, were collected 1h and 24h after intramuscular
njection of Cy5-labelled plasmid (pDNA-Cy5) or unlabelled con-
rol plasmid (pDNA). Cell suspensions and tissue sections were
xamined for the presence pDNA-Cy5 by ﬂow cytometry and ﬂuo-
escence microscopy (data not shown), respectively. We detected
xtensive Cy5+ signal in muscle 1h after injection using ﬂuores-
ence microscopy (data not shown). The signal was predominantly
etween muscle bundles and within myocytes, as has been shown
y others previously [19]. During the preparation of the labelled
DNA we removed any unbound Cy5 by extensive washing and
hus we are conﬁdent that Cy5 signal distribution corresponds
ith pDNA distribution. 1h post-pDNA-Cy5 injection, we observed
ell-associated pDNA-Cy5 in popliteal, inguinal and distal periph-
ral LNs by ﬂow cytometry with the largest numbers found in the
ocalmuscle-draining popliteal LNs (Fig. 5A,middle panel, asterisks
how samples with cell-associated pDNA-Cy5). Cell suspensions
rom the different tissues of individual mice (n=3 mice per group
or each timepoint) were gated on live cells (based on forward
nd side scatter plots) and positive and negative gates were set
sing cell suspensions from equivalent tissues collected from mice
njected with unlabelled pDNA (Fig. 5A, top panel). We observed a
ewpDNA-Cy5+ cells in peripheral blood, but noneweredetected in
pleen or bone marrow at this timepoint. This result suggested that
ome pDNA rapidly enters the peripheral blood from the injection
ite. Fluorescence microscopy of popliteal lymph nodes showed
abelled DNA in the subcapsular sinus and throughout paracortical
reas (data not shown), as has been described previously [19], sug-
esting that injected pDNA drains into the proximal lymph nodes
ia the afferent lymphatic vessels. In all cases, cell suspensions
rom unlabelled pDNA-immunised mice showed very little back-
round staining (<0.04%). At 24h we found pDNA-Cy5-containing
ells in draining (popLN and ILN) and distal peripheral lymph
odes (Fig. 5A, bottom panel). As observed for the 1h timepoint,
he popliteal LN contained the highest percentage of positive cells
∼0.4% live cells). Although we were unable to ﬁnd cell-associated
DNA in the peripheral blood at 24h, we were able to demonstrate
ositive cells in both the spleen and bonemarrow at this timepoint.In other experiments, we attempted to characterise the cells
ssociatedwithpDNA-Cy5usingmulticolour ﬂowcytometry. Anal-
sis of draining and distal LNs and spleen at 24h indicated that
hey were CD45/Ly5+ (haematopoietic), MHC Class II+, CD11b+
nd mostly B220−, although a few B220+ cells were also asso-PB + + NDa ND ND
BM + − + − −
a Not determined—too few cells to phenotype further.
ciated with pDNA-Cy5 (Fig. 5B and Table 1). pDNA was rarely
found in CD11chigh cells, suggesting that monocytic cells, possi-
bly macrophages or immature monocytes (CD11b+, CD11c−) are
the predominant cell type initially associated with pDNA follow-
ing intramuscular DNA injection. Too few pDNA-Cy5+ cells were
found in peripheral blood to phenotype. pDNA in bonemarrowwas
restricted to CD45/Ly5+, CD11b+,MHCClass II−, which is suggestive
of an immature myeloid/monocyte cell phenotype. Data presented
from one experiment (n=3 per group) shows that the percentage
of pDNA-Cy5+ cells is statistically increased in both popliteal LN
and spleen at 24h (Fig. 5C). The percentage is increased in 2 out
of 3 mice in the BM but does not reach statistical signiﬁcance. In
summary, pDNA is cell-associated in LNs draining the injection,
in more distal LNs, in peripheral blood, spleen and BM, thus sug-
gesting that pDNA is widely disseminated following intramuscular
injection and hence there are multiple pathways for pDNA to reach
secondary lymphoid tissue.
3.6. Detection of Ag and cells displaying pMHC complexes
following DNA injection
We (this study), and others [1], have observed pMHC-bearing
cells in peripheral lymph nodes soon after a single immunisa-
tion of soluble protein Ag, with large numbers of CD11c+ cells
bearing pMHC complexes at 24h post-injection. Thereafter the
number of pMHC+ cells declines and reaches background levels by
about 7 days post-immunisation (data not shown). We wanted to
determine if this same strategy was sufﬁciently sensitive to detect
pMHC+ cells following DNA injection where small amounts of anti-
gen are produced in vivo, in contrast to bolus injection of protein
Ag. We were speciﬁcally interested in both the kinetics of appear-
ance and the anatomical distribution of pMHC complex-bearing
cells following pDNA injection.
Flow cytometric analysis of live cells from pooled peripheral
lymph nodes collected 3 days after pCI-ERFP injection, revealed a
small population of Y-Ae+CD11c+ cells, representing 0.34% of live
cells (Fig. 6A, upper right quadrants). pCIneo-immunised mice and
isotype (mIgG2b) controls showedonly background staining (0.03%
and 0.11%, respectively). The proportion of Y-Ae+CD11c+ cells in
pCI-ERFP-immunised mice (i.e. 0.34%) is comparable to that seen
3 days after immunisation with ERFP protein, i.e. several days
after the peak of pMHC complex display. Results from one exper-
iment (n=2) are shown in Fig. 6B and other experiments (n=3)
showed a similar trend. The percentage of Y-Ae+CD11c+ cells is
higher in pCI-ERFP-immunised mice compared to both pCIneo-
immunised mice and for isotype control staining. The percentage
of Y-Ae+CD11c− cells in pCI-ERFP-immunised mice was no dif-
ferent to that observed for pCIneo-immunised mice (Fig. 6A, upper
left quadrants), suggesting that the only cells that display pMHC
complexes in DNA immunised mice are CD11c+ cells, presumably
dendritic cells. This is in contrast to what we observed following
ERFP and EGFP protein immunisation, where about 1% of live
cells are Y-Ae+CD11c− (Figs. 6A and 1B).Whenwe gated on CD11c+
cells from draining lymph nodes of pCI-ERFP- and ERFP protein-
immunised mice at day 3 following injection, we observed that
approximately 14% and 12% respectively of these CD11c+ cellswere
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Fig. 5. pDNA distribution and phenotype of pDNA-containing cells following plasmid injection. (A) Tissues including the TA muscle, draining popliteal (popLN) and inguinal
lymph nodes (ILN), distal brachial and cervical lymph nodes (distal LNs), spleen, peripheral blood and bone marrow were collected 1h and 24h following intramuscular
injection of Cy5-labelled (pDNA-Cy5) or unlabelled control pDNA. Cell suspensions were examined for the presence pDNA-Cy5 by ﬂow cytometry. Live cell gates (determined
by forward and side scatter characteristics) were drawn and cell suspensions from mice receiving unlabelled pDNA were used to set cutoffs for positive and negative gates
and represented background tissue staining. Cy5 ﬂuorescence was assessed using the FL4 channel of the FACScalibur and cells with above background ﬂuorescence were
considered positive. (A) Cy5 ﬂuorescence (X-axis) vs. side scatter (Y-axis) for representative samples from various tissues at 2 different timepoints. At 1h we observed
pDNA-Cy5 in popliteal, inguinal and distal peripheral lymph nodes with largest numbers in the local muscle-draining popliteal LN. We also observed a few pDNA-Cy5+
cells in peripheral blood, but none were detected in either spleen or bone marrow. Asterisk (*) indicates tissues with Cy5+ cells. At 24h post-pDNA-Cy5 injection we found
Cy5+-cells indraining anddistal peripheral lymphnodes. Thepopliteal LN contained thehighest percentageof positive cells. Althoughwewereunable toﬁndpDNA-containing
C.M. Rush et al. / Vaccine 28 (2010) 1620–1634 1629
Fig. 6. Detection of pMHC complexes in lymphoid tissue following DNA injection. (A) Flow cytometric analysis of pooled peripheral lymph nodes collected 3 days after
pCI-ERFP injection, revealed a small population of Y-Ae+CD11c+ cells (upper right quadrant), representing approximately 0.3% of live cells. pCIneo-immunised mice and
isotype (mIgG2b) controls showed only background staining (0.03% and 0.11%, respectively). The proportion of Y-Ae+CD11c+ cells in pCI-ERFP-immunised mice (i.e. 0.34%)
is comparable to that seen 3 days after immunisation with ERFP protein, i.e. several days after the peak of pMHC complex display. pCIneo-immunised mice and isotype
(mIgG2b) controls showed only background staining (typically <0.1%). Results from one experiment (n=2) are shown in (B) and other experiments (n=3) showed a similar
trend. The percentage of Y-Ae+CD11c+ cells is higher in pCI-ERFP-immunised mice compared to both pCIneo-immunised mice and for isotype control staining. Analysis of
CD11c+ gated cells (C) showed that approximately 14% and 12% of CD11c+ cells were also Y-Ae+ for pCI-ERFP and ERFP protein, respectively. Although the percentage of
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fD11c+ cells displaying pMHC was similar, the pattern of Y-Ae expression was qu
RFP protein immunisation, relative to its’ isotype control, whereas only a discret
xpression following pCIneo immunisation.
-Ae+ (Fig. 6C). Although the percentage of CD11c+ cells display-
ng pMHC complexes was similar, the pattern of Y-Ae expression
as quite different. We observed a shift in Y-Ae expression for the
ntire population following ERFP protein immunisation, relative
o its’ isotype control, whereas only a discrete population was pos-
tive following pCI-ERFP injection. These cells were RFP− (data
ot shown), suggesting that the ERFP protein had already been
rocessed or was below the level that we could detect by ﬂow
ytometry. There was little change in Y-Ae expression following
CIneo immunisation.
We could detect antigen GFP expression at the muscle injection
ite, 24h after pDNA injection by immunoﬂuorescencemicroscopy.
FP+ muscle cells could be easily distinguished from the autoﬂuo-
escentoxidativeﬁbres [20] (Fig. 7AandB)andwerepredominantly
ound in thevicinityof the injectionsite, as evidencedby the inﬂam-
atory inﬁltrate at the needle trajectory (Fig. 7B). Others have
eported Ag expression in non-muscle, mononuclear cells of the
ells in the peripheral blood at 24h, we were able to demonstrate positive cells in both
mmunised mice shown that pDNA-Cy5+ cells from the popLN and spleen were MHCII+,
Students’ unpaired t-test, 2 way, assuming unequal variance) were made between the
rom unlabelled mice. (C) The mean percentage of Cy5+ cells in popLN, spleen and BM. Asferent. We observed a shift in Y-Ae expression for the entire population following
lation was positive following pCI-ERFP injection. There was little change in Y-Ae
perimysium [21] however we were unable to conﬁrm GFP expres-
sion in these cells. We observed small clusters of GFP+ cells in
draining popliteal LNs at 24h post-injection, however ampliﬁca-
tion of the GFP signal using anti-GFP Ig was required to visualise
these rare cells (Fig. 7C). These results suggest pDNA-encoded Ag
is in the tissue draining lymph node as early as 24h post-injection.
As previously described for the EGFP system, we could detect
Y-Ae+ ERFP+ cells in the subcapsular sinus (Fig. 7D) and paracorti-
cal areas of draining LNs, 24h after ERFP injection. Howevermany
Y-Ae+ cells in the T cell areas were ERFP negative, suggesting that
Ag had already been processed and hence no longer ﬂuorescent,
or that these cells contained levels of ERFP below the limits of
detection by immunoﬂuorescence microscopy. We observed cells
of a similar phenotype, Y-Ae+ERFP−, in mice immunised with
pCI-ERFP. Three days after plasmid injection, we detected rare,
sparsely distributed Y-Ae+ERFP− cells in the subcapsular sinus
of draining inguinal lymph nodes (Fig. 7E and F). No staining was
the spleen and BM. Further characterisation of cell suspensions from pDNA-Cy5
whereas those from BM were predominantly MHCII− (B). Statistical comparisons
percentage of Cy5+-live cells in pDNA-Cy5 injected mice and background staining
terisk (*) indicates statistical signiﬁcance where p<0.05 (n=3).
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Fig. 7. Detection of Ag and pMHC complexes in tissue sections of pDNA-immunised mice. At different times after injection of pCI-ERFP, pCI-EGFP or pCIneo, we collected
and processed TA muscle and draining and distal lymph nodes for immunoﬂuorescence microscopy. GFP expression was observed at the muscle injection site, 24h after
pDNA injection (A and B). GFP+ muscle cells were predominantly found in the vicinity of the injection site, as evidenced by the inﬂammatory inﬁltrate at the needle trajectory
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aB). DAPI was used in (A) and (B) to stain cell nuclei. (C) Using anti-GFP IgG, we obs
D) We observed Y-Ae+ cells in the subcapsular sinus of ERFP protein-immunise
njection (blue). No staining was observed in pCIneo-immunised mice or using the
he references to colour in this ﬁgure legend, the reader is referred to the web versi
bserved in pCIneo-immunised mice or using the isotype con-
rol, mIgG2b (data not shown). We were unable to conclusively
emonstrate pMHC+ cells in the T cell areas of peripheral lymph
odes or spleen, presumably because the level of pMHC complex
n these very rare cells was below the sensitivity of detection of
he immunoﬂuorescence staining protocol.
.7. E˛-speciﬁc T cells accumulate and blast as early as 3 days
ollowing DNA injection
Others have shown previously that Ag dose has consequences
or both the number of pMHC complexes generated and T cell
ctivation in vivo and hence we were interested to know if the
pparently low level pMHC we observed on CD11c+ cells was sufﬁ-
ient for T cell activation and whether the pMHC complex staining
e observed 3 days after DNA injection correlated temporally with
he activation of E-speciﬁc CD4+ T cells. We also wanted to estab-
ish the precise anatomical localisation and kinetics of CD4+ T cell
ctivation and proliferation following intramuscular DNA injection
nd hence determine the relationship between pDNA distribution,small clusters of GFP protein in draining popliteal LNs at 24h post-injection (red).
e at 24h (blue) and (E and F) in pCI-ERFP-immunised mice at d3 post-plasmid
e control, mIgG2b (data not shown). Scale bars show 10m. (For interpretation of
the article.)
pMHC+ cells andTcell activation. Thereforeweusedadoptive trans-
fer of E-speciﬁc TEa T cells and kinetic analysis of activation and
cell division following injection with E-expressing plasmids, to
readout antigen presentation in vivo. The TEa TcR recognises the
same pMHC complex as the Y-Ae mAb [12] and thus the initial
activation/blastogenesis of these cells should be a good indication
of the ﬁrst time these cells see Ag, i.e. the precise timing of Ag
presentation.
At early timepoints (e.g. 12h), we observed a transient upreg-
ulation of surface CD69 in both non-Tg and Tg CD4 T cells
in pCI-ERFP- and pCIneo-immunised mice, indicative of DNA-
induced non-speciﬁc activation (data not shown). However by 24h
surface CD69 had returned to control levels (data not shown). At
d3 post-immunisation, we observed an increase in the percent-
age of E-speciﬁc Tg T cells in draining LNs (pooled popliteal
and inguinal), distal peripheral LNs and the spleens of pCI-ERFP-
and pCI-EGFP-immunised mice (Fig. 8A). No such increase was
observed in the pCIneo group. This increase in the %Tg preceded
cell division as no CFSE dye dilution was observed by d3 (data not
shown). We speculate that this is indicative of retention of E-
C.M. Rush et al. / Vaccine 28 (2010) 1620–1634 1631
Fig. 8. pDNA induces CD4 T cell proliferative responses early after intramuscular immunisation. To readout Ag presentation to CD4+ T cells in vivo, we transferred CFSE-
labelled E-speciﬁc TEa T cells into B6 recipients and analysed the kinetics of T cell activation and cell division following injection with E-expressing plasmids. Mice that
had received CFSE-labelled TEa Tg T cells 1 day previously, were immunised with pCI-ERFP, pCI-EGFP or the control plasmid pCIneo. Draining lymph nodes (popliteal
and inguinal), distal peripheral lymph nodes (cervical, brachial and axial) and the spleen were collected at different times after immunisation (12h–10 days) and analysed
by ﬂow cytometry for blastogenesis, clonal expansion and division of Tg lymphocytes. (A) At d3 post-immunisation we observed an increase in both the percentage and
blastogenesis of E-speciﬁc Tg T cells in draining LNs (pooled popliteal and inguinal), distal peripheral LNs and the spleens of pCI-ERFP- and pCI-EGFP-immunised mice.
No such increases were observed in the pCIneo group. (B and C) We observed division of TEa T cells in draining and distal lymph nodes and spleen at d5, d7 and d10 post-
immunisation following injectionwith pCI-ERFP but not the control plasmid pCIneo. Kinetic analysis of cell division (C) revealed that by day 5 post-pCI-ERFP immunisation
E-speciﬁc lymphocytes in the popLN and spleen had started to divide, and this number had increased by days 7 and 10. In contrast E-speciﬁc lymphocytes in distal lymph
nodes has increased in number by day 7, but no further increased was observed at day 10. Cells from pCIneo-immunised mice showed only background staining at all
timepoints. Error bars show standards errors and asterisk (*) indicates statistical signiﬁcance compared to pCIneo-immunised group.
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peciﬁc T cells or inhibition of T cell egress from the lymphoid
issues, due to stable APC-T cell interactions as we [22], and oth-
rs [23] have noted in other T cell priming regimes. There was no
orresponding increase in the percentage of non-Tg CD4+ T cells
n draining LNs (Fig. 8A), distal peripheral LNs or spleen (data
ot shown), suggesting that the TEa accumulation we observed
as Ag-driven. Concomitantly, we observed signiﬁcant blasto-
enesis of E-speciﬁc T cells, in all tissues of pCI-ERFP and
CI-EGFP-immunised mice (Fig. 8A). No TEa blasts were found in
CIneo-immunised groups. These results are strongly suggestive of
resentation E peptide to E-speciﬁc CD4+ T cells at d3 following
lasmid vaccination and that T cells in the draining, and distal LNs
nd spleen have seen Ag by this time.
Inorder todetermine if therewereanydifferences in thekinetics
f T cell activation in these anatomically distinct lymphoid tissues,
e analysed cell division history using adoptive transfer of CFSE-
abelled TEa T cells. By d5 we observed E-speciﬁc T cell division in
raining lymph nodes, but little division in more distal peripheral
Ns and the spleen (Fig. 8B and C). However by d10 we found TEa
ivision in all lymphoid tissues examined, with the highest propor-
ion of divided cells being found in the spleen. Thus although the
cell response to pDNA-encoded Ag appears to commence in the
ocal draining lymph nodes, this is superceded by responses in the
pleen.We also examined intermediate timepoints, and have never
bserved the multiple division peaks, typically found when using
FSE for T cell proliferation, suggesting that the E-speciﬁc T cells
ad divided in a different location and once divided had migrated
o the tissues examined, or that very few naïve re-circulating T
ells synchronously enter cell division, presumably due to limit-
ng amounts of Ag. Only when they have divided more than 6 times
ave they accumulated sufﬁciently for us to detect cell division.
e were unable to ﬁnd evidence for Ag presentation at timepoints
ther than d3. These results correlatewith the appearance of pMHC
omplexes in draining lymphnodes, hence fromour data it appears
hat Ag presentation peaks 3 days after DNA immunisation.
. Discussion
Thekeyevents in the initiationof an immune response following
DNA vaccination include cell transfection and pDNA dissem-
nation, Ag expression in somatic and/or haematopoietic cells,
g acquisition by APCs, presentation of peptide/MHC complexes
pMHC) to naïve T lymphocytes in secondary lymphoid tissue,
evelopment of effector and memory phenotype and function and
ognate interactions between Ag-speciﬁc CD4 T cells and B cells
esulting in high afﬁnity antibody production. Despite extensive
nvestigations demonstrating that immune responses are induced
y many experimental DNA vaccines and that their character and
agnitude can be readily manipulated, many of the processes
oted above, related to DNA vaccines are still a “black box” with
espect to the precise cell phenotypes, cell–cell interactions and
natomical and temporal aspects of the initiation and maintenance
f DNA vaccine immune responses. Studies such as these are difﬁ-
ult because of the paucity of tools necessary to investigate these
ow frequency events, but crucial for the rational design and appli-
ationofDNAvaccines.Wehave therefore appliedavarietyof novel
ools to address these questions directly in vivo for the ﬁrst time.
.1. Anatomical distribution of pDNAFollowing intramuscular injection, free and cell-associated
DNAhasbeen found inmuscle, peripheral blood [24], lymphnodes
raining the injection site [19] and other sites including the bone
arrow [25], minutes to months after injection [19,26–28]. Simi-
ar to others [19], we found labelled, cell-associated pDNA in the8 (2010) 1620–1634
peripheral blood within 1h of DNA injection and within cells of
distal LNs, spleen and bone marrow by 24h. We have not excluded
the possibility that cells may be responsible for pDNA transport
to the spleen and bone marrow, however our ﬁnding of pDNA in
peripheral blood within 1h suggests that pDNA is carried as free
DNA.
Contrary to recent reports [29] we found no evidence for
naïve CD4 T cell priming in the BM following pDNA injection.
Our ﬁnding of pDNA-bearing cells in this site may have impor-
tant consequences for both mobilisation of APC precursors from
the BM into the periphery, as well as the maintenance of long-
term memory following DNA vaccination. Our data suggests that
CD11b+B220−MHCIIlow cells in the BM acquire pDNA. This phe-
notype is consistent with monocytes or neutrophils [30] which
migrate from sites of inﬂammation to the BM and lead to antigen
presentation directly or following engulfment by another APC [30].
4.2. Characterisation of APC expressing pMHC
Although it is understood that DNA vaccines result in sus-
tained Ag expression at the site of injection [31], in some cases
more than 12 months [16,31–34], the exact contribution of this
Ag to initiating and maintaining immune responses is far from
clear. The cell types engaged in antigen production following intra-
muscular pDNA injection are predominantly myocytes, although
direct transfection of, and antigen expression by, haematopoi-
etic cells (including CD11b+ cells) at the injection site, has been
reported [21,35,36]. Although it is believed that somatic cells such
as myocytes serve as Ag factories, that continue to “tickle” naïve
and perhaps memory cells, precisely how and when Ag gets from
these Ag depots to CD4 and CD8 T cells in secondary lymphoid tis-
sue is not clear. One of the reasons why this has been difﬁcult to
study, relates to the small amounts of Ag available for presentation
at any given time which is in the nanogram range [17,34,37,38].
We demonstrated GFP expression in myocytes surrounding the
injection sitewithin 24h of DNA injection andwere able to demon-
strate very rare cells containing the model Ag EGFP in lymph
nodes draining the muscle injection site at 48h after injection
(Fig. 7C) though this was at the limit of our carefully controlled
detection systems. Because these cells were very rare and difﬁ-
cult to detect, we were unable to conﬁrm whether they themselves
had expressed the Ag, or had acquired Ag from another cell, nor
could we deﬁnitively phenotype and further characterise these
cells. However, their location within the LN paracortex and their
dendritic appearance, suggests they may be dendritic cells and
potentially able to present Ag to naïve T lymphocytes. Single cell
analysis using sensitive techniques such real-time PCR may be par-
ticularly informative for determining precisely which cells express
the acquired DNA and hence the contribution of direct versus cross
priming for priming DNA vaccine-induced antigen presentation.
Hence the identity of the cell presenting DNA-encoded antigen
to naïve T cells remains controversial and there appear to be roles
for Ag presentation both by directly transfected dendritic cells and
by antigen transfer from somatic cells to APCs [39,40,41].
As noted above antigen dose and persistence has signiﬁcant
functional consequences for the development of long-lived mem-
ory lymphocytes and hence is an important consideration for DNA
vaccine design. Brief exposure to high amounts of Ag is often
associated with the rapid expansion of effector CD8 T cells but
limited development of long-lived memory T cells, whereas pro-
longed exposure to lower Ag amounts, can induce higher numbers
of (central) memory cells [9,42,43]. In other studies, the precursors
of long-lived memory CD4 T cells were shown to undergo lower
degrees of cellular activation following their ﬁrst Ag encounter, and
thiswas a consequence of their exposure to lowamounts of Ag [44].
Thus achieving the ideal balance between Ag dose, persistence and
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cell activation is a very important and complex consideration for
accines.
This led us to evaluate the minimal requirements, with respect
o Ag dose and number of peptide–MHC-bearing cells necessary
o elicit immune responses in vivo and to relate this to what we
ee following DNA injection. We utilised and adapted a strategy
or identifying cells displaying pMHC complexes using ﬂuorescent
eporters, E-peptide, pMHC Ab Y-Ae and E-speciﬁc T cells. Itano
t al. [1], reported that the induction of immune responses, fol-
owing immunisation with the ERFP protein, was characterised
y two distinct waves of Ag presentation and that optimal T cell
ctivation required both phenomena. In this previous study, ERFP
owing into the draining LN from the injection site was processed
nd displayed on the surface of LN CD11c+ cells within minutes
hereas LN migrants from the skin injection site (dermal DCs)
rrived 12–24h after immunisation. It was this second wave of
MHC+ cells that was essential for full CD4+ T cell differentiation
nd effector function. We observed very similar kinetics using our
GFP fusion protein, to that reported previously and following
he initial appearance of GFP+ and Y-Ae+ cells in the draining LNs
t 1–4h, these cells decreased until 12–24h when a second wave
f migrants arrived from the injection site. By 24h we observed
arge numbers of Y-Ae+ cells, although they showed considerable
eterogeneity with respect to both GFP and CD11c expression.
his may reﬂect different states of maturation and/or different
ell lineages (e.g. myeloid DC vs. pDC). Although we observed Y-
e+ and GFP+ cells in non-draining LNs (data not shown), the low
requency of these cells highlights how Ag distribution and thus
ffective Ag dose, has important consequences for the location
nd/or duration of Ag presentation. Similarly, when we immunised
ith different Ag doseswe observed rapid diminution of our ability
o detect cell-associated Ag and pMHC complexes with decreasing
g dose. Ag doses lower than 100g substantially decreased our
bility to detect GFP+ or Y-Ae+ cells within both the CD11c+ and
D11clow/− populations, however we were conﬁdent that we could
etect cells from these unpuriﬁed cell suspensions down to a dose
f 1g–100ng. Selective enrichment of Y-Ae+ cells may further
mprove the sensitivity of these analyses.
Collectively, our results using EGFP (and ERFP) protein, high-
ight the impact of Ag dose and distribution and importance of
etailed kinetic analyses for detecting rare pMHC cells in vivo. Nev-
rtheless, we did detect rare pMHC+CD11c+ cells in the peripheral
Ns of pDNA-immunised mice, 3 days after injection. In contrast
o the clearly deﬁned, although heterogeneous, Y-Ae+ cells we
bserved 24h after protein injection, we did not observe a discrete
opulation of pMHChigh cells, but rather an increase in Y-Ae ﬂuo-
escence intensity of about 14% of CD11c+ cells. This was similar to
hat we observed 72h after protein immunisation, when Ag was
imiting.Wewereunable todemonstrateCD11c+pMHC+ cells in tis-
ue sections, which was not particularly surprising as we observed
nly a slight increase in ﬂuorescence intensity by ﬂow cytometry.
owever, we observed dispersed Y-Aehigh cells in the subcapsu-
ar sinus of draining LNs, 3 days after injection of E-expressing
lasmids. Due to the scarcity of these cells we were unable to phe-
otype them further, but their location in the subcapsular sinus
uggests they had migrated to the LNs in afferent lymphatics or
ere subcapsular sinus resident macrophages [45,46].
.3. Characterisation of the early T cell response
Antigen-speciﬁcTcells are transiently “enriched” in thedraining
ymph nodes and Ag-containing tissue sites during the early stages
f an immune responsedue to changes in thebalance between lym-
hocyte ingress and egress [47]. Our ﬁnding that E-speciﬁc T cells
ccumulate in peripheral LNs and spleen, 3 days after injection of
-expressing plasmids, suggests that these cells are involved in (2010) 1620–1634 1633
Ag-speciﬁc interactions with Ag-bearing APCs. This is unlikely to
be simply the result of LN shut down [48–50] as the proportion of
non-Tg CD4 T cells was unaltered at this timepoint (Fig. 8A). We
routinely observe enlarged, hypercellular peripheral LNs between
24 and 48h after immunisation with all plasmids, including pCI-
neo (data not shown), presumably due to CpG-driven non-speciﬁc
inﬂammation, however we believe that the accumulation and/or
inhibition of egress at d3 is Ag-driven and is indicative of ongoing
Ag presentation. We also observed E-speciﬁc TEa blastogenesis
at d3 and cell division by d4/d5, which is further indicative of
Ag presentation occurring by d3. We were unable to ﬁnd pMHC+
cells in the spleen, but the fact that we observed concomitant T
cell accumulation and blastogenesis in draining LNs, distal LNs and
spleen indicates that these things are happening at diverse loca-
tions simultaneously. T cell division in the draining LNs preceded
that in the distal LNs and spleen which suggest that although T
cells appear to be activated at sites distal to the tissue injection
site, perhaps they do not receive sufﬁcient stimulus, Ag dose or
inﬂammation-driven co-stimulation at these earliest time points,
to enter cell cycle. While further experiments are required to con-
clusively determine that cells are dividing at these sites in situ, and
have not just migrated, the fact that pDNA reaches lymph nodes
distal to the injection site and the spleen, is suggestive of Ag pre-
sentation in situ.
We cannot rule out Ag presentation, after d3, but we were
unable to ﬁnd pMHC+ cells after this timepoint. Increasing the sen-
sitivity of the Y-Ae detection method may reveal a longer duration
of presentation. The duration of antigenic stimulus determines the
fate of naïve and effector cells, in terms of whether T cells will
be activated or deleted. We know that Ag persists in the injec-
tion site and potentially the draining lymph node for many weeks,
and therefore it is possible that naïve, re-circulating Ag-speciﬁc T
cells may be subsequently exposed to Ag upon passage through
Ag-containing lymphoid tissues, although this will depend on their
precursor frequency. Whether or not these subsequently activated
cells contribute to the effector or memory response is unclear.
Recent evidence suggests that naïve CD4+ T cells that enter the
immune response after the peak response, i.e. when Ag is limiting,
divide less on primary response, but are better at responding upon
subsequent Ag challenge, and acquire a long-lived central memory
phenotype [44]. This may parallel what happens with DNA vac-
cines,where Ag is limiting and althoughprimary effector responses
are often weak, memory responses are usually good [11].
We have presented in vivo, for the ﬁrst time a highly detailed
description of the early events following DNA vaccination and this
has considerable implications for the rational development,manip-
ulation and application of DNA vaccination. Our data is consistent
with the followingscenario. InjectedDNAvaccines rapidlyenter the
peripheral blood fromthe injection site but also reach lymphoid tis-
sues directly as free DNA via the afferent lymphatics. The relatively
large molecular size of pDNA probably precludes it from ﬂowing
into the conduits of LNs, and therebyLNresidentDCs fromsampling
it directly, but rather it may be taken up by cells in the subcapsular
sinus that then migrate into deeper areas of the LN such as the DC
and T cell-containing interfollicular and paracortical areas. pDNA
and/or expressed Ag may then be transferred from these cells to
CD11c+ DCs for presentation to naïve T cells. Concomitantly, blood-
borne DNA reaches the bone marrow and spleen where it is taken
up by CD11b+MHCIIlow cells (monocytes/myeloid DC precursors).
The bone marrow may then act as a reservoir for cell-associated
pDNA or its presence may induce the maturation and mobilisa-
tion of monocytes/myeloid DC precursors into the periphery. The
observation that naïve CD4 T cells in draining and distal LNs and
spleen “see” Ag simultaneously, suggests that pMHC complexes are
widely distributed and the rapid dissemination of pDNA may be
the reason for this. Although we were unable to precisely identify
1 cine 2
a
i
a
v
A
P
c
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[49] MartIn-FontechaA, Sebastiani S,HopkenUE,UguccioniM, LippM,Lanzavecchia634 C.M. Rush et al. / Vac
nd deﬁnitively link the cells acquiring, expressing and present-
ng DNA-encoded Ag, due to the minute amounts of Ag involved
nd the rarity of these cells, they are clearly able to initiate DNA
accine-induced immune responses.
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